google translate.....
Zhejiang Haixiang Pharmaceutical Co., Ltd.
Announcement on Industry Fund's Participation in Vaccine R&D Cooperation
The company and all members of the board of directors guarantee the truthfulness, accuracy and completeness of the information disclosed, and there is no falsehood
Records, misleading statements or major omissions.
risk warning:
1. According to the current domestic approval requirements for vaccine products, vaccine products need to complete preclinical research,
Clinical trial approval, clinical phase I, phase II and/or phase III trials, marketing approval, production facility certification/
Only check (if applicable) and other links before listing. The development and marketing cycle of vaccine products is generally long.
2. The products developed by this cooperation are still in the pre-clinical research stage, which may be due to safety, effectiveness and/
Or technical quality and other issues terminated, there is uncertainty. According to vaccine development experience, the clinical
There is a risk of failure in all stages of pre-research and clinical trial research. The sales of the vaccine after the market is also
Affected by many factors such as the market environment and sales channels, sales are also uncertain.
1. Basic situation of cooperation
Recently, Zhejiang Haixiang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"
received Beijing Guoxin Haixiang
Notice of Equity Investment Partnership (Limited Partnership) (hereinafter referred to as "Industry Fund": Industry Fund is
Joint United States Generex Biotechnology Company, Beijing Youfeng International Consulting Co., Ltd. and China Disease
The Institute for Viral Disease Prevention and Control of the Center for Disease Control and Prevention has jointly developed vaccines. The vaccine products are currently in the development stage.
The announcement will be made on the official website of Generex Biotechnology in the United States.
This matter does not constitute a connected transaction, nor does it constitute the provisions of the "Administrative Measures for the Major Asset Restructuring of Listed Companies"
Major asset reorganization. The amount of foreign investment this time did not reach the "Shenzhen Stock Exchange Stock Listing Rules"
According to the prescribed standards for disclosure, this matter does not need to be submitted to the company's board of directors and shareholders' meeting for review.
2. Introduction of partners
1. Beijing Guoxin Haixiang Equity Investment Partnership (Limited Partnership) is managed by Beijing Guoxin Zhongshu Investment
The limited company and the company jointly initiated the establishment. Beijing Guoxin Zhongshu Investment Management Co., Ltd. is the general industry fund
Through partner, the company is a limited partner of an industrial fund.
2. Generex Biotechnology is a comprehensive healthcare holding company that provides
A patient-centric end-to-end solution that quickly diagnoses personalized therapy. Generex is building a
A new type of healthcare system, the company will go beyond the traditional model to provide support for physicians in the MSO network,
And maintain an ongoing relationship with the patient to improve the patient experience and get the best care.
3. The Institute for Viral Disease Control and Prevention of the Chinese Center for Disease Control and Prevention is a subsidiary of the Chinese Center for Disease Control and Prevention
The independent legal entity is the only national-level viral disease prevention and control and medical virology research in China
mechanism.
4. Beijing Youfeng International Consulting Co., Ltd. is mainly engaged in the industrialization of high-tech achievements and the transnational medical industry
Bilateral and multilateral services for enterprises, providing strategic development consulting and design, project cooperation for product and project cooperation in all aspects
Project landing and management.
Except for industry funds, the company has no associated relationship with the other companies mentioned above.
3. The impact of this cooperation on the company
The industry fund unites all parties to introduce international patent technology to participate in vaccine research and development cooperation, which is an industry fund exploration
Attempts to industrialize biomedical innovation technology. The products of R&D cooperation are still in the pre-clinical research stage and exist
With many uncertainties, there is a risk of investment failure.
The company itself is not involved in vaccine research and development, and the industry fund participates in vaccine research and development cooperation. This cooperation will enable
Participation with funds from fund products will not have a significant impact on the company's recent financial and operating conditions.
Four, risk warning
1. According to the current domestic approval requirements for vaccine products, vaccine products need to complete preclinical research,
Clinical trial approval, clinical phase I, phase II and/or phase III trials, marketing approval, production facility certification/
Only check (if applicable) and other links before listing. The development and marketing cycle of vaccine products is generally long.
2. The products developed by this cooperation are still in the pre-clinical research stage, which may be due to safety, effectiveness and/
Or technical quality and other issues terminated, there is uncertainty. According to vaccine development experience, the clinical
There is a risk of failure in all stages of pre-research and clinical trial research, and the sales of vaccines after the market are also
Affected by many factors such as the market environment and sales channels, sales are also uncertain.
The company will disclose the follow-up progress in a timely manner in accordance with the relevant laws and regulations according to the degree of progress of cooperation matters
Happening. Investors are requested to make cautious decisions and pay attention to investment risks.
Special announcement.
Zhejiang Haixiang Pharmaceutical Co., Ltd.
Board of Directors
November 17, 2020
Zhejiang Haixiang Pharmaceutical Co., Ltd.
Announcement on Industry Fund's Participation in Vaccine R&D Cooperation
The company and all members of the board of directors guarantee the truthfulness, accuracy and completeness of the information disclosed, and there is no falsehood
Records, misleading statements or major omissions.
risk warning:
1. According to the current domestic approval requirements for vaccine products, vaccine products need to complete preclinical research,
Clinical trial approval, clinical phase I, phase II and/or phase III trials, marketing approval, production facility certification/
Only check (if applicable) and other links before listing. The development and marketing cycle of vaccine products is generally long.
2. The products developed by this cooperation are still in the pre-clinical research stage, which may be due to safety, effectiveness and/
Or technical quality and other issues terminated, there is uncertainty. According to vaccine development experience, the clinical
There is a risk of failure in all stages of pre-research and clinical trial research. The sales of the vaccine after the market is also
Affected by many factors such as the market environment and sales channels, sales are also uncertain.
1. Basic situation of cooperation
Recently, Zhejiang Haixiang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"
received Beijing Guoxin Haixiang Notice of Equity Investment Partnership (Limited Partnership) (hereinafter referred to as "Industry Fund"
: Industry Fund is Joint United States Generex Biotechnology Company, Beijing Youfeng International Consulting Co., Ltd. and China Disease
The Institute for Viral Disease Prevention and Control of the Center for Disease Control and Prevention has jointly developed vaccines. The vaccine products are currently in the development stage.
The announcement will be made on the official website of Generex Biotechnology in the United States.
This matter does not constitute a connected transaction, nor does it constitute the provisions of the "Administrative Measures for the Major Asset Restructuring of Listed Companies"
Major asset reorganization. The amount of foreign investment this time did not reach the "Shenzhen Stock Exchange Stock Listing Rules"
According to the prescribed standards for disclosure, this matter does not need to be submitted to the company's board of directors and shareholders' meeting for review.
2. Introduction of partners
1. Beijing Guoxin Haixiang Equity Investment Partnership (Limited Partnership) is managed by Beijing Guoxin Zhongshu Investment
The limited company and the company jointly initiated the establishment. Beijing Guoxin Zhongshu Investment Management Co., Ltd. is the general industry fund
Through partner, the company is a limited partner of an industrial fund.
2. Generex Biotechnology is a comprehensive healthcare holding company that provides
A patient-centric end-to-end solution that quickly diagnoses personalized therapy. Generex is building a
A new type of healthcare system, the company will go beyond the traditional model to provide support for physicians in the MSO network,
And maintain an ongoing relationship with the patient to improve the patient experience and get the best care.
3. The Institute for Viral Disease Control and Prevention of the Chinese Center for Disease Control and Prevention is a subsidiary of the Chinese Center for Disease Control and Prevention
The independent legal entity is the only national-level viral disease prevention and control and medical virology research in China
mechanism.
4. Beijing Youfeng International Consulting Co., Ltd. is mainly engaged in the industrialization of high-tech achievements and the transnational medical industry
Bilateral and multilateral services for enterprises, providing strategic development consulting and design, project cooperation for product and project cooperation in all aspects
Project landing and management.
Except for industry funds, the company has no associated relationship with the other companies mentioned above.
3. The impact of this cooperation on the company
The industry fund unites all parties to introduce international patent technology to participate in vaccine research and development cooperation, which is an industry fund exploration
Attempts to industrialize biomedical innovation technology. The products of R&D cooperation are still in the pre-clinical research stage and exist
With many uncertainties, there is a risk of investment failure.
The company itself is not involved in vaccine research and development, and the industry fund participates in vaccine research and development cooperation. This cooperation will enable
Participation with funds from fund products will not have a significant impact on the company's recent financial and operating conditions.
Four, risk warning
1. According to the current domestic approval requirements for vaccine products, vaccine products need to complete preclinical research,
Clinical trial approval, clinical phase I, phase II and/or phase III trials, marketing approval, production facility certification/
Only check (if applicable) and other links before listing. The development and marketing cycle of vaccine products is generally long.
2. The products developed by this cooperation are still in the pre-clinical research stage, which may be due to safety, effectiveness and/
Or technical quality and other issues terminated, there is uncertainty. According to vaccine development experience, the clinical
There is a risk of failure in all stages of pre-research and clinical trial research, and the sales of vaccines after the market are also
Affected by many factors such as the market environment and sales channels, sales are also uncertain.
The company will disclose the follow-up progress in a timely manner in accordance with the relevant laws and regulations according to the degree of progress of cooperation matters
Happening. Investors are requested to make cautious decisions and pay attention to investment risks.
Special announcement.
Zhejiang Haixiang Pharmaceutical Co., Ltd.
Board of Directors
November 17, 2020
1
